BR112012021857A2 - formas cristalinas para sal de sódio de 5-amino-2,3-di-hidro ftalazino-1,4-diona, preparações farmacêuticas contendo o mesmo e processo para a produção das ditas formas - Google Patents

formas cristalinas para sal de sódio de 5-amino-2,3-di-hidro ftalazino-1,4-diona, preparações farmacêuticas contendo o mesmo e processo para a produção das ditas formas

Info

Publication number
BR112012021857A2
BR112012021857A2 BR112012021857A BR112012021857A BR112012021857A2 BR 112012021857 A2 BR112012021857 A2 BR 112012021857A2 BR 112012021857 A BR112012021857 A BR 112012021857A BR 112012021857 A BR112012021857 A BR 112012021857A BR 112012021857 A2 BR112012021857 A2 BR 112012021857A2
Authority
BR
Brazil
Prior art keywords
forms
amino
sodium salt
producing
pharmaceutical preparations
Prior art date
Application number
BR112012021857A
Other languages
English (en)
Other versions
BR112012021857B1 (pt
Inventor
Astrid Kaiser
Beate Ludescher
Gerrit Maass
Josef Breu
Michael Niedermaier
Thomas Martin
Wolfgang Brysch
Wolfgang Milius
Original Assignee
Metriopharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43828190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012021857(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Metriopharm Ag filed Critical Metriopharm Ag
Publication of BR112012021857A2 publication Critical patent/BR112012021857A2/pt
Publication of BR112012021857B1 publication Critical patent/BR112012021857B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)

Abstract

formas cristalinas para sal de sódio de 5-amino-2,3di-hidro ftalazino-1,4-diona, preparações farmacêuticas contendo o mesmo e processo para produção das ditas formas. a invenção refere-se à provisão de duas novas formas cristalinas i eii para sal de sódio de 5-amino-2,3-di-hidro ftalazino-1,4-dino. surpreendentemente, foi verificado que forma i e forma ii têm diferentes efeitos imunológicos. esta propriedade vantajosa é útil para aplicações imunoespecíficas. em edição, ambas formas têm vantajosas propriedades físico-químicas, que são úteis na produção, ainda processamento e/ou uso de uma preparação farmacêutica de forma i ou forma ii ou uma mistura de ambas.
BR112012021857-3A 2010-03-01 2011-03-01 Formas cristalinas para sal de sódio de 5-amino-2,3-di-hidro ftalazino-1,4-diona, seus processos de produção, e preparações farmacêuticas BR112012021857B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10002067 2010-03-01
EP10002067.6 2010-03-01
EP10075744 2010-11-25
EP10075744.2 2010-11-25
PCT/EP2011/001124 WO2011107295A1 (de) 2010-03-01 2011-03-01 Kristalline formen zu 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
BR112012021857A2 true BR112012021857A2 (pt) 2016-05-17
BR112012021857B1 BR112012021857B1 (pt) 2021-06-22

Family

ID=43828190

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012021857-3A BR112012021857B1 (pt) 2010-03-01 2011-03-01 Formas cristalinas para sal de sódio de 5-amino-2,3-di-hidro ftalazino-1,4-diona, seus processos de produção, e preparações farmacêuticas

Country Status (23)

Country Link
US (2) US8772294B2 (pt)
EP (2) EP2774920A1 (pt)
JP (2) JP6061081B2 (pt)
KR (1) KR101770011B1 (pt)
CN (3) CN105859634B (pt)
AU (1) AU2011223226B2 (pt)
BR (1) BR112012021857B1 (pt)
CA (1) CA2791327C (pt)
CH (1) CH704794B1 (pt)
CY (1) CY1115585T1 (pt)
DK (1) DK2542535T3 (pt)
ES (1) ES2487221T3 (pt)
HK (2) HK1223929A1 (pt)
HR (1) HRP20140752T1 (pt)
IL (1) IL221680A (pt)
NZ (1) NZ601689A (pt)
PL (1) PL2542535T3 (pt)
PT (1) PT2542535E (pt)
RS (1) RS53492B1 (pt)
RU (1) RU2585677C2 (pt)
SI (1) SI2542535T1 (pt)
WO (1) WO2011107295A1 (pt)
ZA (1) ZA201206264B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2542535T1 (sl) * 2010-03-01 2014-09-30 Metripharm Ag Kristalinične oblike natrijeve soli 5-amino-2,3-dihidroftalazin-1,4-diona, farmacevtski pripravki, ki jih vsebujejo, in postopek za njihovo pripravo
JP2017537958A (ja) * 2014-12-18 2017-12-21 メトリオファーム アーゲー ５−アミノ−２，３−ジヒドロフタラジン１，４−ジオンナトリウム塩の結晶形態、同一物を含む医薬製剤、及びこの形態の製造ための方法
CN109563052A (zh) * 2016-02-16 2019-04-02 麦翠奥制药公司 5-氨基-2,3-二氢噻嗪-1,4-二酮的结晶体
ES2796476T3 (es) * 2016-02-16 2020-11-27 Metriopharm Ag Procedimiento para la producción de una forma cristalina de 5-amino-2,3-dihidroftalazina-1,4-diona
EP3248602A1 (en) 2016-05-26 2017-11-29 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae
RU2625267C1 (ru) * 2016-09-22 2017-07-12 Общество с ограниченной ответственностью "АБИДАФАРМА" Способ производства нестерильных субстанций безводного "тамерита" и/или двухводного "галавита" - натриевых солей 5-амино-2,3-дигидрофталазин-1,4-диона (варианты) и способы дальнейшей их переработки в стерильные лекарственные препараты
CA3042956A1 (en) * 2016-11-07 2018-05-11 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis
CN106810501B (zh) * 2017-01-23 2019-09-10 湖北新德晟材料科技有限公司 一种利用一锅法合成鲁米诺或异鲁米诺的方法
RU2635769C1 (ru) * 2017-02-08 2017-11-15 Адмир Мусаевич Абидов Лекарственный препарат на основе 5-амино-2,3-дигидрофталазин-1,4-диона в виде быстрорастворимой пленки для трансбуккального введения
RU2673452C1 (ru) * 2017-08-15 2018-11-27 Межрегиональное общественное учреждение "Институт инженерной физики" Способ получения активной фармацевтической субстанции, представляющей собой аминодигидрофталазиндион натрия
EP3511325A1 (en) 2018-01-11 2019-07-17 MetrioPharm AG Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
EP3870175A1 (en) * 2018-10-26 2021-09-01 Immunopharma Plus D.o.o Oral aminodihydrophthalazinedione compositions and their use the treatment of non-viral hepatitis
EP3858328A1 (en) 2020-01-31 2021-08-04 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases
EP3858358A1 (en) 2020-01-31 2021-08-04 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases
IL296058A (en) 2020-03-25 2022-10-01 Metriopharm Ag 5-amino-2,3-dihydro-1,4-phthalazinedione for the treatment of acute lung injury
WO2021249667A1 (en) 2020-06-10 2021-12-16 Metriopharm Ag Compound for the treatment of coronaviral infections
EP3981405A1 (en) 2020-10-08 2022-04-13 MetrioPharm AG Compound for the treatment of coronaviral infections
CA3183225A1 (en) 2020-07-09 2022-01-13 Wolfgang Brysch Glucocorticoid-sparing agent
EP4255391A1 (en) 2020-12-02 2023-10-11 MetrioPharm AG Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection
RU2756568C1 (ru) * 2021-03-24 2021-10-01 Акционерное общество "Щелково Агрохим" Способ получения натриевой соли 5-амино-2,3-дигидро-1,4-фталазиндиона в гидратированной или безводной форме
EP4193994A1 (en) 2021-12-08 2023-06-14 MetrioPharm AG Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections
EP4209219A1 (en) 2022-01-07 2023-07-12 MetrioPharm AG Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione
EP4248963A1 (en) 2022-03-25 2023-09-27 MetrioPharm AG Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a fumaric acid ester

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1089086C (zh) * 1988-03-31 2002-08-14 兰德尔·L·米尔斯 鲁米纳得类药物
CH683966A5 (it) 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanze attive in agenti anti-ipossici e di difesa.
CH683965A5 (it) 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
RU2113222C1 (ru) 1997-09-30 1998-06-20 Закрытое акционерное общество "Центр современной медицины "Медикор" Иммуномодулирующее средство
RU2138264C1 (ru) 1999-05-06 1999-09-27 Абидов Муса Тажудинович Способ получения лекарственного препарата галавит
DE60142541D1 (de) 2000-03-28 2010-08-26 Abidov Musea Tazhudinovich Arzneimittel und dessen herstellungsprozess
RU2167659C1 (ru) 2000-08-02 2001-05-27 Закрытое акционерное общество "Центр современной медицины "Медикор" Способ коррекции иммунной системы живого организма
RU2169139C1 (ru) 2000-08-02 2001-06-20 Закрытое акционерное общество "Центр современной медицины "Медикор" Способ получения щелочных и щелочноземельных солей 5-амино-2,3-дигидро-1,4-фталазиндиона
RU2211036C2 (ru) 2001-11-20 2003-08-27 Общество с ограниченной ответственностью "Абидофарма" Лекарственный препарат (варианты) и способ его производства
RU2222327C2 (ru) 2002-03-22 2004-01-27 Общество с ограниченной ответственностью "Абидофарма" Способ получения лекарственного препарата
US7326690B2 (en) 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
RU2238730C1 (ru) 2003-02-17 2004-10-27 Абидов Муса Тажудинович Лекарственный препарат
RU2302863C2 (ru) 2003-04-18 2007-07-20 Общество с ограниченной ответственностью "Абидофарма" Лекарственный препарат (варианты)
CN1217193C (zh) * 2003-07-30 2005-08-31 中国药科大学 心肌肌钙蛋白鲁米诺化学发光免疫分析检测方法
US8592421B2 (en) 2003-08-04 2013-11-26 Valery Khazhmuratovich Zhilov Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
PL231885B1 (pl) 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
EP2393361B1 (en) 2009-02-06 2016-12-07 Bach Pharma, Inc. Pharmaceutical grade phthalazinediones, process for their preparation and pharmaceutical compositions containing them
SI2542535T1 (sl) 2010-03-01 2014-09-30 Metripharm Ag Kristalinične oblike natrijeve soli 5-amino-2,3-dihidroftalazin-1,4-diona, farmacevtski pripravki, ki jih vsebujejo, in postopek za njihovo pripravo

Also Published As

Publication number Publication date
US8772294B2 (en) 2014-07-08
EP2774920A1 (de) 2014-09-10
PL2542535T3 (pl) 2014-10-31
HK1223929A1 (zh) 2017-08-11
BR112012021857B1 (pt) 2021-06-22
CN105726541A (zh) 2016-07-06
KR101770011B1 (ko) 2017-08-21
RS53492B1 (en) 2015-02-27
RU2012141274A (ru) 2014-04-20
DK2542535T3 (da) 2014-07-28
CA2791327C (en) 2018-10-30
HK1223836A1 (zh) 2017-08-11
EP2542535A1 (de) 2013-01-09
ES2487221T3 (es) 2014-08-20
JP6206689B2 (ja) 2017-10-04
AU2011223226B2 (en) 2015-04-23
US9079863B2 (en) 2015-07-14
WO2011107295A1 (de) 2011-09-09
EP2542535B1 (de) 2014-05-07
NZ601689A (en) 2014-11-28
HRP20140752T1 (hr) 2014-10-24
CN105859634A (zh) 2016-08-17
CN102971300A (zh) 2013-03-13
JP2016196483A (ja) 2016-11-24
CN102971300B (zh) 2016-03-02
CY1115585T1 (el) 2017-01-04
CA2791327A1 (en) 2011-09-09
JP6061081B2 (ja) 2017-01-18
PT2542535E (pt) 2014-08-25
ZA201206264B (en) 2016-07-27
AU2011223226A1 (en) 2012-10-25
IL221680A0 (en) 2012-12-02
RU2585677C2 (ru) 2016-06-10
US20140303169A1 (en) 2014-10-09
CN105859634B (zh) 2019-06-28
SI2542535T1 (sl) 2014-09-30
KR20130019383A (ko) 2013-02-26
US20120329801A1 (en) 2012-12-27
IL221680A (en) 2015-09-24
CH704794B1 (de) 2013-04-15
JP2013521239A (ja) 2013-06-10

Similar Documents

Publication Publication Date Title
BR112012021857A2 (pt) formas cristalinas para sal de sódio de 5-amino-2,3-di-hidro ftalazino-1,4-diona, preparações farmacêuticas contendo o mesmo e processo para a produção das ditas formas
BR112014008045A2 (pt) benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas
BR112012023660B8 (pt) usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer
GT201300186A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
BR112015026830A8 (pt) composto, composição farmacêutica, combinação, produto, uso de um composto, e, método para profilaxia ou tratamento de um estado de doença ou condição
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
CR10298A (es) Metodos y composiciones para antagonismo de rage
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
UY30711A1 (es) Nuevos derivados de 1,4-benzotiepina-1, 1-cioxido, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.-
BR112015020787A2 (pt) inibidores quinazolínicos de formas mutantes ativantes do receptor do fator de crescimento epidérmico
BR112012010706A2 (pt) composto, composição farmacêutica, combinação do produto farmacêutico, uso de um composto, e, métodos para o tratamento de uma doença ou condição, e para inibir um bromodomínio
BR112015014453A2 (pt) produtos de cuidado oral compreendendo cloreto de zinco tetrabásico e trimetilglicina
BR112014011162A2 (pt) derivados purínicos para o tratamento de infecções virais
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
UY30712A1 (es) Nuevos derivados de 1, 4-benzotiepina-1, 1-dioxido sustituidos con fluor, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.
UY30710A1 (es) Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales ciclohexilo, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.
BR112012013431A2 (pt) composto, composição farmacêutica e seu uso
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112012027509A2 (pt) composto, processo para a preparação de composto, composição farmacêutica, uso de composto, e, método
UA111588C2 (uk) Композиція інгібітора jak для місцевого застосування
BR112014010206B8 (pt) composto derivado de piridopirazina, composição farmacêutica, e, uso de um composto
GT201400111A (es) Triazolopiridinas sustituidas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/03/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.